Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man

Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction

(2015) Robert W. Yeh et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

(2015) Marc P. Bonaca et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor

(2012) S. NYLANDER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Vorapaxar in the Secondary Prevention of Atherothrombotic Events

(2012) David A. Morrow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer Agent

(2012) Jing Ni et al.   Cancer Discovery

Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel

(2011) N. S. KIRKBY et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes

(2011) Pierluigi Tricoci et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of ticagrelor and thienopyridine P2Y12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis

(2009) J.J.J. van Giezen et al.   THROMBOSIS RESEARCH